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 A 18F Radiolabelled Zn(II) Sensing Fluorescent Probe 
Thomas W. Price,a‡ George Firth,a‡ Charlotte J. Eling,b Michelle Kinnon,a Nicholas J. Long,c Justin 
Sturge,a and Graeme J. Stasiuka*.
A selective fluorescent probe for Zn(II), AQA-F, has been 
synthesized. AQA-F exhibits a ratiometric shift in emission of up to 
80 nm upon binding Zn(II) ([AQA-F] = 0.1 mM, [Zn(II)Cl2 = 0-300 M). 
An enhancement of quantum yield from Φ = 4.2% to Φ = 35% is also 
observed. AQA-F has a binding constant, Kd = 15.2 M with Zn(II). 
This probe has been shown to respond to endogenous Zn(II) levels 
in vitro in prostate and prostate cancer cell lines. [18F]AQA-F has 
been synthesized with a radiochemical yield of 8.6% and a 
radiochemical purity of 97% in 88 minutes. AQA-F shows the 
potential for a dual modal PET/fluorescence imaging probe for 
Zn(II). 
Prostate cancer (PCa) is the 2nd most common cancer 
worldwide for males, with >161,000 new cases in the US in 2017 
(19% of male cancer cases; 10% of total cancer cases).1 
Diagnosis and active surveillance of PCa involves measurement 
of serum levels of prostate specific antigen (PSA), with invasive 
biopsies used for determination of the prognostic Gleason 
Score. Novel, simple diagnostic tests are needed to catch the 
disease early and this may be achieved by assessing 
endogenous Zn(II) levels. 
Zn(II) has been identified as a key metal in a range of biological 
functions;2,3 its homeostasis is maintained by a number of 
proteins including Zrt-like Irt-like proteins (ZIP) and cation 
diffusion facilitators (CDF).4 Overabundance of Zn(II) is 
implicated in a number of diseases (e.g. Alzheimer’s disease,5 
diabetes6 and PCa7). Zn(II) has emerged as a promising 
diagnostic target in PCa progression as the homeostasis of Zn(II) 
is disrupted in diseased tissue.8,9  
The largest concentration of Zn(II) is found in the prostate gland 
(total Zn(II) concentration = 800-1500 M)10 where uptake from 
extracellular fluids is controlled by the Zrt-like Irt-like Protein 1 
(ZIP1) transporter.7 Mutation of the tumor suppressor gene 
SLC39A1 (encoding ZIP1) downregulates ZIP1 protein levels in 
PCa tissue, leading to 62–75% lower levels of Zn(II) 
accumulation.9 This significant decrease in malignant tissue 
allows for the potential diagnosis of prostate cancer through 
measurement of the Zn(II) concentration in the prostate. 
Over the last two decades, research into probes which give an 
indication of disease progression by responding to different 
concentrations of Zn(II) has become a key area of interest.11,12,13 
A plethora of optical probes for Zn(II) have been developed;14–
23 typically by modifying organic fluorophores to include Zn(II) 
sensing units. Modification of fluorescein by addition of 
dipicolylamine (DPA) units produced a high affinity fluorescence 
based probe, ZP1.24 Further development led to ZPP1 which 
demonstrates a ratiometric based detection of zinc with a 10 
nm shift in emission.25 Compartmentalisation of zinc in diseases 
has been highlighted by similar probes.26 
Scheme 1: Synthesis of AQA-F 
 
Combining these optical probes with an additional imaging 
modality can improve the properties of the probe.27,28 In 
particular, the pairing of PET and optical imaging can allow for 
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direct cellular validation of the PET probe.27,29 Whilst 
radiolabelling of optical probes is well reported,29–33 few 
examples of “smart” dual modal optical-PET probes are present 
in the literature.31,34,35  
The quinoline-based AQZ probe developed by Zhang et al.36 is 
an organic fluorophore and Zn(II) chelator showing excellent 
ratiometric fluorescence properties upon Zn(II) binding. AQZ 
has recently been shown attached to a MRI chelate as a dual-
modal probe for diagnosis of diabetes.37 The Zn(II) binding 
properties of AQZ were retained after functionalization through 
the terminal alcohol group. 
Figure 1. Fluorescence spectra of AQA-F (0.1 mM, λex = 320 nm) 
in HEPES buffer (10 mM, pH 7.68) solution in the presence of 
increasing concentrations of Zn(II) (0-3 equivalents, 2.5-300 M, 
n = 3). 
 
We herein report the development of a fluorinated fluorescent 
probe, AQA-F, which upon binding Zn(II) exhibits a change in 
emission profile allowing endogenous Zn(II) levels to be 
monitored. Furthermore, we have undertaken preliminary 
radiolabeling studies to demonstrate the feasibility of 
producing [18F]AQA-F. This Zn(II) sensor is designed to set the 
foundation for a dual modal PET/fluorescence probe for 
prostate cancer diagnosis. 
AQA-F was synthesized in 4 steps from 2-fluoroethanol (Scheme 
1). The fluorinated chain 2-(2-fluoroethoxy)ethan-1-amine 
hydrochloride (6) was prepared by condensation of tert-butyl 
(2-hydroxyethyl)carbamate (3) with 2-fluoroethyl 4-
methylbenzenesulfonate (4) under basic conditions to yield 5 
followed by deprotection under acidic conditions.38 Conjugation 
of 6 to 2-chloro-N-(quinol-8-yl)-acetamide (2), under the same 
conditions reported for the synthesis of AQZ,36 yielded AQA-F in 
an 80% yield. 
AQA-F demonstrated an excitation maximum of 320 nm and an 
emission maximum of 420 nm (Figure S4) with quantum yield, 
Φ = 4.2% (Table S4). Upon Zn(II) binding an 8-fold enhancement 
in fluorescence intensity was observed (Figure 1). This 
fluorescence enhancement (Φ = 35%) was also accompanied by 
a red shift in the emission maxima of 80 nm to 500 nm.  
Three isosbestic points at 243, 278 and 323 nm were observed 
in the absorption spectra for AQA-F upon addition of Zn(II) 
(Figure 2). The ratio of the absorbance at 260 and 278 nm (Inset, 
Figure 2) highlighted the binding of Zn(II) until the addition of 
one equivalent; following this, the ratio began to plateau. This 
indicates that AQA-F binds Zn(II) in a 1:1 molar ratio with a Kd of 
15.2 M.  
A decrease in fluorescence intensity was observed at acidic pH 
due to protonation of the secondary amine (pKa = 6.62, Figure 
3). This protonation also limits Zn(II) binding; there is no 
increase in fluorescence intensity in the presence of Zn(II) at 
acidic pH. The fluorescence intensity begins to increase at pH 6 
(pKa = 6.86), with the maximum intensity observed in the 
physiological pH window which is promising for biological  
Figure 2. Absorption spectra of AQA-F (0.1 mM) in HEPES buffer 
(10 mM, pH 7.68) in the presence of increasing concentrations 
of Zn(II) (0-3 equivalents, 2.5-300 M, n = 3). 
 
applications. Above pH 8.5 a reduction in fluorescence intensity 
of probe bound to Zn(II) was also observed (pKa= 9.68). This 
decrease could be a result of a deprotonation of a water 
molecule bound to the metal centre.39 
The fluorescent response of AQA-F demonstrates specificity for 
Zn(II) over other divalent metal ions, especially those found in 
biological environments (Figure 4). A small enhancement in the 
emission at 500 nm of AQA-F is seen in the presence of Ca(II). A 
significant increase in fluorescence emission was observed for 
Zn(II). It must be noted that AQA-F has the highest affinity for 
Zn(II) compared to all of these metals (Table S3, Figure S1). 
Figure 3. Fluorescence intensity of AQA-F (0.1 mM, λex = 320 
nm, λem = 500 nm) in KCl (0.1 M) solution with variation of 
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solution pH. Black = AQA-F, Red = AQA-F + 1 equivalent ZnCl2. 
(n = 3) 
 
To validate AQA-F in vitro it was incubated with a healthy 
epithelial prostate cell line (RWPE-1) and a grade IV prostate 
adenocarcinoma cell line (PC-3) (Figure 5, Figure S3). AQA-F is 
internalized by cells following a 30 minute incubation period.  
The change in the emission profile of AQA-F upon binding Zn(II) 
could be used to assess the relative level of Zn(II) in cells. The 
ratio of emission at λem = 500 nm to λem = 420 nm (shown in 
Figure 5) is directly related to the Zn(II) concentration (Figure 1). 
This ratio is greater in the healthy prostate cells than in the PC-
3 cell line (Table S5), indicating a greater Zn(II) concentration in 
the RWPE-1 cell line. This reflects the reduced Zn(II) uptake of 
prostate cancer cells due to the downregulation of the ZIP-1 
Zn(II) transporter.7,9,40 In both cell lines, the ratio increases 
when incubated with additional Zn(II) (Table S5). 
Figure 4. Metal binding assay showing the fluorescence 
response of AQA-F (0.1 mM, λex = 320 nm, λem = 500 nm) in 
HEPES buffer (10 mM, pH = 7.68) upon addition of 1 equivalent 
of metal chloride. (n = 3) 
 
Scheme 2. Synthesis of [18F]AQA-F 
 
A preliminary study to produce [18F]AQA-F (Scheme 2) was 
performed in a two-step process from 8. The first step 
introduces the 18F isotope through nucleophilic substitution at 
the terminal tosylate leaving group, with a radiochemical 
conversion (RCC) of 82.6%, in 15 minutes at 110 oC in anhydrous 
MeCN (Figure S12). Following this, hydrolysis of the Boc 
protecting group under acidic conditions gave [18F]AQA-F with 
a 54.3% RCC (Figure S13). The radiochemical purity after 
purification by semi-preparative HPLC is recorded at 97%, 
(Figure S10), with an isolated radiochemical yield of 8.6% with a 
total synthesis time of 88 minutes, thus showing the 
possibilities for a PET tracer for Zn(II). 
 
Figure 5. A collection of micrographs showing RWPE-1 and PC-3 
cells that have been incubated with 100 M AQA-F and 
Rhodamine Concanavalin A. Scale bar = 50 m. 
 
  
 
AQA-F demonstrates a red shift of 80 nm from 420 nm to 500 
nm when binding Zn(II). This novel probe has been shown to 
bind Zn(II) in a 1:1 ratio with the highest affinity of all the metals 
tested, possessing a Kd of 15.2 M. AQA-F exhibits a 
fluorescence maximum at physiological pH and has been shown 
to be internalized by healthy and cancerous prostate cells 
within 30 minutes. The shift from 420 nm to 500 nm when 
binding Zn(II) allows for differentiation of free probe and Zn(II)-
bound probe through fluorescent microscopy. [18F]AQA-F was 
radiolabelled in 8.6% RCY with radiochemical purity of 97%, 
thus showing the potential for a dual modal PET/fluorescence 
imaging probe for Zn(II). The fluorescent probe, AQA-F, which 
has the potential for the in vitro determination of endogenous 
Zn(II) levels has been synthesized as both a cold standard and 
radiolabelled analogue [18F]AQA-F. 
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